Premium
Maternal use of selective serotonin‐reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn
Author(s) -
Alwan S,
Bandoli G,
Chambers CD
Publication year - 2016
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.376
Subject(s) - persistent pulmonary hypertension , medicine , pregnancy , pulmonary hypertension , population , prenatal exposure , pediatrics , intensive care medicine , gestation , environmental health , biology , genetics
Use of selective serotonin reuptake inhibitors (SSRIs) in late pregnancy has been associated with persistent pulmonary hypertension of the newborn (PPHN), a rare condition with substantial infant mortality and morbidity. Although the increase in absolute risk is small on a population level, it may be of concern to many patients. It remains unclear the extent to which the increased risks reported for PPHN are explained by the underlying maternal illness rather than the use of SSRIs.